Gabelli Funds LLC Decreases Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Gabelli Funds LLC lowered its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 5.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 181,974 shares of the health services provider's stock after selling 9,937 shares during the period. Gabelli Funds LLC owned approximately 0.56% of Amedisys worth $16,521,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AMED. Vanguard Group Inc. boosted its holdings in Amedisys by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider's stock worth $291,992,000 after purchasing an additional 10,817 shares during the last quarter. Norges Bank bought a new stake in shares of Amedisys in the fourth quarter worth $83,061,000. Alpine Associates Management Inc. increased its position in Amedisys by 3.2% during the fourth quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider's stock valued at $80,632,000 after acquiring an additional 27,403 shares during the last quarter. Wealthfront Advisers LLC bought a new position in Amedisys in the fourth quarter valued at about $72,970,000. Finally, Alliancebernstein L.P. boosted its position in Amedisys by 2.0% in the fourth quarter. Alliancebernstein L.P. now owns 677,787 shares of the health services provider's stock worth $61,536,000 after purchasing an additional 13,587 shares during the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Price Performance

Shares of AMED traded down $0.03 during mid-day trading on Monday, reaching $91.74. The stock had a trading volume of 16,609 shares, compared to its average volume of 398,873. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of 36.40, a PEG ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The business has a fifty day moving average of $92.14 and a 200 day moving average of $91.86. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $598.05 million during the quarter, compared to analysts' expectations of $602.38 million. Equities analysts predict that Amedisys, Inc. will post 4.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AMED. Stephens restated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Amedisys has a consensus rating of "Hold" and a consensus target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.